


Prevention Strategies for Device-Related Infections



John Conly MD

Professor of Medicine, Microbiology, Immunology & Infectious Diseases

Pathology & Laboratory Medicine

University of Calgary

Apr 2015

Objectives

- 1.To understand the principles and need for antimicrobial prophylaxis for implantable devices
- 2.To outline the preventive strategies for device associated infections
- 3.To be aware of the research gaps in the prevention of device-associated infections

Disclosures

- Clinical reviewer and co-investigator: CADTH (*C. difficile* and MRSA projects)
- Grants/Contracts: AI-HS, EuroAspire Program, NCCID, PHAC, Sanofi
- Speaker or Participant (last 3 years): Pfizer, BioMerieux, Merck
- Consultant: WHO (AGISAR, GIPC Network)

Case presentation

- An 84 year old female admitted from Pacemaker Clinic to FMC Aug 2012 with pain and swelling over the pacemaker site
 - Background of osteoporosis, atrial fibrillation and anticoagulation, hypertension with LVH and LV diastolic dysfunction, moderate AI, moderate pulmonary hypertension, mild CAD
 - Pacemaker inserted for AF with slow ventricular response and syncope FMC June 2011 ; minor complication of proximal perforation of cephalic vein otherwise unremarkable
 - Meds: ASA, Bisoprolol, Enalapril, Furosemide, Levothyroxine, Nortriptyline, Warfarin, Nitropatch

Case presentation

- Previous admission RGH ICU Apr 2012 for fever, rigors and hypotension and found to have MSSA bacteremia ; all investigations negative for source including TTE ; treated parenteral cloxacillin
- Readmitted RGH MTU late May 2012 with lassitude and malaise ; blood cultures + MSSA ; full workup for source including TEE , nuclear medicine scans all negative
- Referred to HPTP for 6 weeks cloxacillin

Case presentation

- Physical findings of dusky erythema , warmth and boggiess over the pacemaker site
- Infectious diseases consulted and recommended aspiration
- US revealed complex fluid mass
- Small amount fluid obtained – many PMNs and scant g + cocci with growth *S. aureus*
- OR Aug 17 and pacemaker capsule, pacemaker and lead tip all + MSSA
- New VVI pacemaker on August 24 and cloxacillin for 6 weeks ; remained well 1 year



Types of Device-Related Infections

- Intravenous catheter associated (peripheral, midline, central, umbilical, tunneled and non tunneled, ports)
- Implantable cardiac devices (pacemakers, defibrillators, assist devices)
- Urinary tract catheters (upper and lower)
- Chest devices (ETTs, chest tubes, pleurocaths)
- GI tract (stents) and CNS devices (shunts and deep brain stimulators)
- Orthopedic implants

Guidelines

- CDC/HICPAC
- Compendium of Strategies to Prevent HAI(SHEA/IDSA/APIC/SIS/SHM/others)
- PHAC
- IHI 5 Million Lives from Harm
- Others
 - AHA: CV Implantable Electronic Device Infections
 - Hydrocephalus Clinical Research Network
 - Surgical Infection Prevention Project

<http://www.shea-online.org/PriorityTopics/CompendiumofStrategiestoPreventHAIs.aspx>

<http://www.ihi.org/engage/initiatives/Pages/default.aspx>


<http://phac-aspc.gc.ca/dpg-eng.php#infection>

<http://www.cdc.gov/hicpac/pubs.html>


Pathogenesis of SSI

- $\frac{\text{Inoculum of bacteria} \times \text{Virulence}}{\text{Resistance of the host}} = \text{SSI Risk}$
- Primary source of SSI pathogens: endogenous flora (skin, mucous membranes, hollow viscera)
- Exogenous sources of SSI pathogens
 - Operating room environment
 - Surgical personnel (mainly surgical team)
 - Tools, instruments, materials


Cross Section of Abdominal Wall Depicting CDC Classification of SSI



Pathogenesis of CRI



Pathogenesis of CRI




Pathophysiology of Device-Related Infection (SSI or CRI)

- Microbe related factors
- Host related factors
- Operative/insertion risk factors (includes device related)

Microbe Related Factors

- Inherent virulence
- Adherence properties
- Production of biofilms
- Innate immunity defences



Host Risk Factors

- Extremes of ages(age < 1 year or > 60 years)
- Poor nutritional status/obesity
- Co-morbidities and severity underlying illness
- Systemic steroids/chemotherapy/radiotherapy
- Coincident remote site infection
- Length of stay
- Perioperative transfusion of blood products
- Loss skin integrity (more for line-related)

Operative/Insertion Risk Factors

- Duration of scrub
- Pre-op shaving and skin antisepsis
- Duration of surgery/procedure
- Prophylaxis and its timing
- OR ventilation
- Sterilization of instruments
- Foreign material in site/presence drains
- Surgical technique

Device-Related Risk Factors

- Type of device material
- Frequency of surface irregularities
- Thrombogenicity of device materials
- Use of antibiotic or antiseptic impregnated devices
- Duration of use (longer duration > risk)
- Type and site of placement (cutdown > percutaneous; emergent > elective)

Preventing Device-Related SSIs



Preoperative

- Administer antimicrobial prophylaxis according to evidence-based standards and guidelines (I)
 - Begin administration within 1 hour before incision
 - Select agents based on the procedure and the most common pathogens
 - Discontinue agent within 24 hours
- Do not remove hair at the operative site unless necessary and no razor use (II)
- Use alcohol-containing preoperative skin prep if no contraindication exists (I)
 - Alcoholic chlorhexidine may be preferred

Principles of Antimicrobial Prophylaxis

- The operation should carry a significant risk of SSI and/or cause significant bacterial contamination or an SSI would be catastrophic
- Use an agent that is safe, inexpensive, and bactericidal for likely pathogens
- The shortest course of the most effective and least toxic antibiotic should be used
- The antibiotic chosen must achieve concentrations $>$ than the MIC of the suspected pathogens in the wound site and be present at the time of incision

Prophylaxis: Agents, Timing


- 1st and 2nd generation cephalosporins most commonly used agents
- Avoid broad spectrum agents
- General consensus: Administer within 60 min before incision
 - Previously except C-section, after cord clamping but now before clamping (2010)
 - Except vancomycin, infusion time may take longer

Preoperative

- Educate surgeons and perioperative personnel about SSI prevention(III)
 - Education on sterile technique and surgical scrubbing especially housestaff
- Educate patients and their families about SSI prevention (III)
- Implement policies/practices that align with evidence-based standards (II)

Preoperative

- Implement policies/practices that align with evidence-based standards (II)
 - Optimal preparation and disinfection of the operative site and the hands of the surgical team members
 - Adherence to hand hygiene prior to application of skin prep in the OR
 - Reduce unnecessary traffic in the OR
 - Appropriate care and maintenance of operating rooms, including appropriate air handling and optimal cleaning and disinfection of equipment and the environment



Perioperative

- Maintain normothermia (temperature of 35.5° C or more) during the perioperative period (I)
 - Mild hypothermia risk for SSI
 - Also reduces intraop blood loss
- Optimize tissue oxygenation by administering supplemental oxygen (I)

Perioperative

- Use impervious plastic wound protectors for gastrointestinal and biliary tract surgery (I)
- Use a checklist (eg WHO) to ensure compliance with best practices (I)
- Implement policies/practices that align with evidence-based standards (II)
 - Reduce unnecessary traffic in the OR (maintain theatre discipline)
 - Appropriate care and maintenance of operating rooms

What is theatre discipline ?

- Poor theatre discipline^{1,2}
 - Jewelry wearing and artificial nails
 - Open isolation gowns in theatre
 - No masks in theatre
 - Personal cameras in OR adjacent to incisions
 - Improper handling of medical devices
 - Too many personnel in the theatre
 - Frequent and unnecessary entry/exit from OR

¹Recommended practices for preoperative patient skin antisepsis. In: Perioperative Standards and Recommended Practices. Denver, CO: AORN, Inc; 2013:75-90

²Crolla RMPH, van der Laan L, Veen EJ, Hendriks Y, van Schendel C, et al. (2012) Reduction of Surgical Site Infections after Implementation of a Bundle of Care. PLoS ONE 7(9): e44599. doi:10.1371/journal.pone.0044599

Dress code policy



Postoperative Factors

- Control blood glucose during the immediate postoperative period (I/II)
- Perform surveillance for SSI (I)
- Increase the efficiency of surveillance using automated data (II)
- Provide feedback of SSI rates (II)
- Provide feedback on rates of compliance with process measures (III)


Unresolved Issues and Research Gaps

- No standard protocol for preoperative showers/baths with an antiseptic agent the night before surgery
- Admission screening *S. aureus*
- RCTs vs quasi-experimental and cohort studies on issues of theatre discipline - major ethical issues
- Optimal device materials to prevent infection

1Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative *Staphylococcus aureus* infections. *N Engl J Med*. 2002 Jun 13;346(24):1871-7.

2Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. *Cochrane Database Syst Rev*. 2012 Sep 12;9:CD004985. doi:10.1002/14651858.CD004985.pub4

Preventing Central Line - Related Infections



Pre-Insertion

- Minimize unnecessary CVC (III)
- Require education of HCEs involved in insertion, care, and maintenance of CVCs (II)
 - Complete educational program and renew at intervals
 - Credentialing
 - Use of simulation
- Bathe ICU patients over 2 months of age with a chlorhexidine preparation daily (I)
 - Role in non ICU patients unknown
 - Unresolved issue in pediatric patients < 2 months

Peri-Insertion

- Process in place to ensure adherence to infection prevention practices at the time of CVC insertion (II)
 - Document adherence to aseptic technique (checklist or direct observation)
- Hand hygiene prior to insertion (II)
- Avoid femoral site (I)
- Use of pre-loaded cart for supplies (II)
- Use US guidance for IJ (II)
- Maximal barrier precautions (II)
- Alcoholic chlorhexidine antiseptic for skin preparation (I)

Post-Insertion

- Ensure appropriate nurse-to-patient ratio and limit the use of float nurses in ICUs (I)
- Disinfect catheter hubs, needleless connectors, and injection ports before accessing the catheter (II)
 - Use CHG or alcohol or PI
 - Friction for no < 5 sec
 - Monitor compliance
- Remove nonessential catheters (II)
- For non-T CVCs Δtransparent dressings and perform site care with a GHG antiseptic q5-7d; gauze q2d; immediately if soiled, loose, or wet (II)

Marschall et al Strategies to Prevent Central Line–Associated Bloodstream Infections in Acute Care Hospitals:

2014 Update Infection Control / Volume 35 / Issue 07 / July 2014, pp 753 – 771 DOI: 10.1086/591059, Published online: 02 January 2015

Post-Insertion

- Replace administration sets not used for blood, blood products, or lipids at intervals no > 96h (I)
- Use antimicrobial ointments for hemodialysis catheter-insertion sites (I)
 - PT triple or PI preferred
 - Do not use mupirocin ungt
- Perform surveillance for CLABSI in ICU and non-ICU settings (I)
 - Measure the unit-specific incidence of CLABSI (CLABSIs per 1,000 catheter-days) and report regularly
 - Benchmark internally and externally

Unresolved Issues and Research Gaps

- Recognition of limitations of the data
- Use of antiseptic and antimicrobial impregnated catheters/hubs and risk of resistance
- Use of antiseptic impregnated dressings if CHG washes used
- Extent of use of antibiotic locks for CVCs
- Routine use needleless connectors to reduce infection risk
- Use of teams for CVL insertion
- Transparent vs dry gauze dressings
- Rise of chlorhexidine and silver resistance

